Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study. Andrea Becciolini , Simone Parisi , Patrizia Del Medico , Antonella Farina , Elisa Visalli , Aldo Biagio Molica Colella , Federica Lumetti , Rosalba Caccavale , Palma Scolieri , Romina Andracco , Francesco Girelli , Elena Bravi , Matteo Colina , Alessandro Volpe , Aurora Ianniello , Maria Chiara Ditto , Valeria Nucera , Veronica Franchina , Ilaria Platè , Eleonora Di Donato , Giorgio Amato , Carlo Salvarani , Simone Bernardi , Gianluca Lucchini , Francesco De Lucia , Francesco Molica Colella , Daniele Santilli , Natalia Mansueto , Giulio Ferrero , Antonio Marchetta , Eugenio Arrigoni , Rosario Foti , Gilda Sandri , Vincenzo Bruzzese , Marino Paroli , Enrico Fusaro , Alarico Ariani Biomedicines（2023）
摘要
Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.
更多 查看译文
关键词
DAPSA, apremilast, psoriatic arthritis
AI 理解论文
溯源树
样例
